$0.29
3.75% yesterday
Nasdaq, May 20, 10:13 pm CET
ISIN
US6904691010
Symbol
OVID
Sector
Industry

Ovid Therapeutics Inc. Stock price

$0.29
+0.00 1.54% 1M
-0.75 72.13% 6M
-0.64 68.96% YTD
-2.85 90.77% 1Y
-1.77 85.93% 3Y
-4.46 93.90% 5Y
-11.96 97.63% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.01 3.75%
ISIN
US6904691010
Symbol
OVID
Sector
Industry

Key metrics

Market capitalization $20.61m
Enterprise Value $-7.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.16
EV/Sales (TTM) EV/Sales -14.47
P/S ratio (TTM) P/S ratio 37.47
P/B ratio (TTM) P/B ratio 0.35
Revenue growth (TTM) Revenue growth 15.73%
Revenue (TTM) Revenue $550.00k
EBIT (operating result TTM) EBIT $-57.02m
Free Cash Flow (TTM) Free Cash Flow $-49.60m
Cash position $43.00m
EPS (TTM) EPS $-0.35
P/E forward negative
P/S forward 82.55
EV/Sales forward negative
Short interest 2.25%
Show more

Is Ovid Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Ovid Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Ovid Therapeutics Inc. forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Ovid Therapeutics Inc. forecast:

Buy
100%

Financial data from Ovid Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.55 0.55
17% 17%
100%
- Direct Costs 0.60 0.60
55% 55%
109%
-0.06 -0.06
93% 93%
-11%
- Selling and Administrative Expenses 24 24
14% 14%
4,313%
- Research and Development Expense 33 33
2% 2%
5,933%
-56 -56
7% 7%
-10,256%
- Depreciation and Amortization 0.60 0.60
55% 55%
109%
EBIT (Operating Income) EBIT -57 -57
8% 8%
-10,366%
Net Profit -25 -25
51% 51%
-4,540%

In millions USD.

Don't miss a Thing! We will send you all news about Ovid Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ovid Therapeutics Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
Topline pharmacodynamic biomarker, safety and tolerability results from a Phase 1 study of OV329 are on track to readout in Q3 2025 Ovid's first program in its KCC2 direct activator library, OV350, has been dosed in a Phase 1 study in Q1 2025; safety and tolerability results expected before year-end Cash, cash equivalents and marketable securities of $43.0 million as of March 31, 2025 are expec...
Neutral
GlobeNewsWire
2 months ago
Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinic Topline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, saf...
Neutral
GlobeNewsWire
3 months ago
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors.
More Ovid Therapeutics Inc. News

Company Profile

Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Head office United States
CEO Jeremy Levin
Employees 23
Founded 2014
Website www.ovidrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today